YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Eledon Pharmaceuticals, Inc. (ELDN) been one of those stocks this year? A quick glance at the compan…
Galderma Group AG - Unsponsored ADR (GALDY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock pric…
As European markets experience volatility amid concerns about AI disruption and digest strong U.S. job data, the pan-European STOXX Europe 600 Index has reached new highs but remains largely unchanged. In this environment, identifying stoc…
In recent weeks, global markets have experienced a mix of volatility and cautious optimism, with U.S. stocks declining amid concerns over AI disruptions and stronger-than-expected job gains dampening hopes for near-term rate cuts. Amid the…
As European markets navigate volatility amid concerns about AI disruption and digest better-than-expected U.S. jobs data, the pan-European STOXX Europe 600 Index has managed to reach new highs, albeit with modest gains. In this environment…
As European markets navigate a landscape marked by volatility and concerns over AI disruption, the pan-European STOXX Europe 600 Index recently reached a new high before settling with modest gains. Amidst these fluctuations, identifying st…
Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland, February 16, 2026--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial…
As European markets continue to show resilience, with the STOXX Europe 600 Index reaching new highs and optimism about the eurozone economy offsetting recent volatility, investors are increasingly focused on identifying potential opportuni…
As the European markets continue to show resilience amid global volatility, optimism about the eurozone economy has supported investor sentiment, with major indices like Germany's DAX and France's CAC 40 posting gains. In this environment…
Galderma unveils We Are All Sculptra, a global campaign capturing the clinical performance of Sculptra® across nine diverse patient profiles and journeys, over two years1 Backed by over 25 years of clinical use, Sculptra continues to prove…
Restylane® Refyne™ and Restylane Defyne™ are the first Optimal Balance Technology (OBT™) hyaluronic acid injectables ever approved and launched in Japan, bringing advanced flexibility and natural movement to the market1,2 This expands Gald…
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lat…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. What recent moves in Galderma Group say about investor sentiment Galderma Group (SWX:GALD) has been…
Results from a global survey of over 4,300 women across five continents presented at IMCAS 2026 reveal a knowledge gap on the impact of menopause on the skin, despite women experiencing around three skin changes during menopause1 Galderma…
Wake Up to Restylane ‘Wake Up To Restylane®’ is a global campaign designed to meet the rising demand for natural-looking always-on results, helping people wake up looking refreshed and rested, and reframes Restylane treatments from a clini…
At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) M…
ZUG, Switzerland, January 21, 2026--(BUSINESS WIRE)--Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the termination of…
[Novo Nordisk office in Fremont, California, USA] JHVEPhoto/iStock Editorial via Getty Images * The ClearBridge International Growth EAFE Strategy underperformed its MSCI EAFE Index benchmark and MSCI EAFE Growth Index secondary benchmark…
As the European market navigates a landscape of mixed economic signals and resilient earnings results, the pan-European STOXX Europe 600 Index has shown modest gains, reflecting cautious optimism among investors. In this environment, ident…
As global markets navigate a mixed landscape with U.S. core consumer prices rising at their slowest pace since 2021 and value stocks outpacing growth for the third consecutive week, investors are keenly observing opportunities that may ari…
Amidst a mixed performance in major European stock indexes, with the STOXX Europe 600 Index ending slightly higher due to resilient economic data and earnings results, investors are keenly observing opportunities for undervalued stocks. In…
Galderma will present data on Relfydess® (RelabotulinumtoxinA) – the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology – which further demonstrate its rapid onset and efficacy through 6 months in both modera…
As the European market shows signs of optimism with major stock indexes rising, investors are keenly observing opportunities that may be trading at a discount. In this environment, identifying undervalued stocks can be crucial for those lo…
Amid continuing optimism about the European economy and company earnings, the pan-European STOXX Europe 600 Index recently ended 2.27% higher, reflecting a favorable interest rate environment. As major stock indexes across Europe rise, ide…
As the pan-European STOXX Europe 600 Index reaches new highs, buoyed by an improving economic environment and closing 2025 with its strongest yearly performance since 2021, investors are increasingly on the lookout for stocks that may be t…
Galderma Group's (VTX:GALD) stock up by 9.6% over the past three months. We wonder if and what role the company's financials play in that price change as a company's long-term fundamentals usually dictate market outcomes. In this article,…
Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab’s fast onset of action and improvement of itch and sleep…
Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause and is associated with very high burden of disease due to severe itch, sleep deprivation and mental distress1 Galderma’s phase I…
L’Oréal Groupe has agreed to acquire an additional 10% stake in Galderma Group, increasing its total interest in the Swiss skincare company to 20%. The additional shares will be purchased from a consortium led by EQT, with the selling part…
If you are wondering whether Galderma Group is still attractive after its big run, or if the easy money has already been made, you are not alone. That is exactly what this valuation deep dive will unpack. The stock has climbed about 4.0% o…
Financial terms weren’t disclosed, but the package of about 24 million Galderma shares would be valued at $4.85 billion based on Friday’s closing price. Continue Reading
PARIS – L’Oréal is delving deeper into aesthetics with the acquisition of another 10 percent stake in Galderma Group AG, the pure-play dermatology leader worldwide and among the largest in injectable aesthetics, which it originally cofound…
Financial terms weren’t disclosed, but the package of about 24 million Galderma shares would be valued at $4.85 billion based on Friday’s closing price. Continue Reading
Robert Way/iStock Editorial via Getty Images * L’Oréal SA (LRLCF [https://seekingalpha.com/symbol/LRLCF]) is doubling its stake in Galderma Group AG (GALDY [https://seekingalpha.com/symbol/GALDY]) to 20%, boosting its investment in the fas…
Galderma Group (SWX:GALD) has been quietly rewarding patient holders, with the stock up about 13% over the past month and roughly 60% year to date, outpacing many healthcare peers. See our latest analysis for Galderma Group. At a share pri…
C. 24 million shares to be sold STOCKHOLM, Dec. 8, 2025 /PRNewswire/ -- Further to previous announcements, an affiliate of the funds known as EQT VIII ("EQT") is pleased to announce it has signed an agreement to sell c. 24 million shares i…